NCT05624710

A Study to Evaluate the Pharmacokinetics and Safety of INCB054707 in Participants With Normal Hepatic Function and Participants With Hepatic Impairment

A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of INCB054707 in Participants With Normal Hepatic Function and Participants With Hepatic Impairment

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 25 (actual)
• Sponsor: Incyte Corporation · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Accepted

Summary

This is a multicenter, open-label, parallel-group study to evaluate INCB054707 in participants with varying levels of renal function or impairment.

Conditions

• Renal Insufficiency
• Kidney Diseases

Interventions

Type	Name	Description
DRUG	INCB054707	INCB054707 75 mg will be administered orally on Day 1.

Timeline

• Start date: 2022-12-08
• Primary completion: 2023-06-30
• Completion: 2023-06-30
• First posted: 2022-11-22
• Last updated: 2025-08-03

Locations

4 sites across 2 countries: United States, Germany

Regulatory

• FDA-regulated drug study